Cited by 220Meta-analysis and systematic reviewsPharmaceutical industry and healthcareAcademic Publishing and Open Access

Frequency and reasons for outcome reporting bias in clinical trials: interviews with trialists

Open access
Smyth, R. M. D., Kirkham, J. J., Jacoby, A., Altman, D. G., Gamble, C., Williamson, P. R.·2011·BMJ

Abstract

OBJECTIVES: To provide information on the frequency and reasons for outcome reporting bias in clinical trials. DESIGN: Trial protocols were compared with subsequent publication(s) to identify any discrepancies in the outcomes reported, and telephone interviews were conducted with the respective trialists to investigate more extensively the reporting of the research and the issue of unreported outcomes. PARTICIPANTS: Chief investigators, or lead or coauthors of trials, were identified from two sources: trials published since 2002 covered in Cochrane systematic reviews where at least one trial analysed was suspected of being at risk of outcome reporting bias (issue 4, 2006; issue 1, 2007, and issue 2, 2007 of the Cochrane library); and a random sample of trial reports indexed on PubMed between August 2007 and July 2008. SETTING: Australia, Canada, Germany, the Netherlands, New Zealand, the United Kingdom, and the United States. MAIN OUTCOME MEASURES: Frequency of incomplete outcome reporting-signified by outcomes that were specified in a trial's protocol but not fully reported in subsequent publications-and trialists' reasons for incomplete reporting of outcomes. RESULTS: 268 trials were identified for inclusion (183 from the cohort of Cochrane systematic reviews and 85 from PubMed). Initially, 161 respective investigators responded to our requests for interview, 130 (81%) of whom agreed to be interviewed. However, failure to achieve subsequent contact, obtain a copy of the study protocol, or both meant that final interviews were conducted with 59 (37%) of the 161 trialists. Sixteen trial investigators failed to report analysed outcomes at the time of the primary publication, 17 trialists collected outcome data that were subsequently not analysed, and five trialists did not measure a prespecified outcome over the course of the trial. In almost all trials in which prespecified outcomes had been analysed but not reported (15/16, 94%), this under-reporting resulted in bias. In nearly a quarter of trials in which prespecified outcomes had been measured but not analysed (4/17, 24%), the "direction" of the main findings influenced the investigators' decision not to analyse the remaining data collected. In 14 (67%) of the 21 randomly selected PubMed trials, there was at least one unreported efficacy or harm outcome. More than a quarter (6/21, 29%) of these trials were found to have displayed outcome reporting bias. CONCLUSION: The prevalence of incomplete outcome reporting is high. Trialists seemed generally unaware of the implications for the evidence base of not reporting all outcomes and protocol changes. A general lack of consensus regarding the choice of outcomes in particular clinical settings was evident and affects trial design, conduct, analysis, and reporting.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/bmj.c7153

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Problems arise when trial protocols do not designate any primary outcome.

    “Problems also arise when trial protocols do not designate any primary outcome, as seen in half of protocols for a sample of trials published from 2002 to 2008,254 and in 18% and 25% of randomised trial protocols that received ethics approval in Switzerland and Denmark, respectively.249 255”
  • Half of protocols for a sample of trials published from 2002 to 2008 did not designate any primary outcome.

    “as seen in half of protocols for a sample of trials published from 2002 to 2008,254”
  • Numerous studies have shown substantive changes between prespecified methods and those reported in trial publications.

    “Numerous studies have shown substantive changes between prespecified methods (eg, as stated in approved protocols, registries, or regulatory agency submissions) and those reported in trial publications, including changes to primary outcomes,254 256 257 475 sample size calculations,200 eligibility criteria,215 216 476 and interventions,477 as well as methods of allocation concealment,329 blinding,5”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Smyth, R. M. D., Kirkham, J. J., Jacoby, A., Altman, D. G., Gamble, C., & Williamson, P. R.
Affiliations
University of Liverpool (GB)
Corresponding author
Williamson, P. R.
Venue
BMJ
Publisher
BMJ
Published
2011-01-06
Volume
342
Issue
jan06 1
Pages
c7153-c7153
ISSN
  • 0007-1447 (ISSN-L)
  • 0959-8138
  • 1468-5833
OpenAlex
W2122793971
Cited by
220
References
33
Citations by year
2026: 3 · 2025: 4 · 2024: 10 · 2023: 14 · 2022: 13 · 2021: 8 · 2020: 10 · 2019: 13 · 2018: 11 · 2017: 14 · 2016: 18 · 2015: 30 · 2014: 14 · 2013: 17 · 2012: 24
FWCI
23.50
Type
journal article
Language
en
Open access
Licence
cc-by-nc
Locations
  • BMJ (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • Research Explorer (The University of Manchester) (acceptedVersion)
Funders
  • Cancer Research UK
  • Medical Research Council
Topics
  • Social Sciences › Decision Sciences › Statistics, Probability and Uncertainty › Meta-analysis and systematic reviews
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmaceutical industry and healthcare
  • Social Sciences › Decision Sciences › Information Systems and Management › Academic Publishing and Open Access
Keywords
selective reporting, clinical trials, research integrity, selective outcome reporting, research ethics training, research ethics policy, research ethics regulation
MeSH terms
Clinical Protocols, Clinical Trials as Topic, Research Design, Research Personnel, Treatment Outcome, Publication Bias

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review